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While current pharmacotherapies are efficacious, there remain a clear shortfall between symptom remission and functional 
recovery. With the explosion in our understanding of the biology of these disorders, the time is ripe for the investigation of 
novel therapies. Recently depression is conceptualized as an immune-inflammatory and nitro-oxidative stress related disorder. 
Minocycline is a tetracycline antibiotic that has anti-inflammatory, pro-oxidant, glutamatergic, neurotrophic and neuroprotective 
properties that make it a viable target to explore as a new therapy. This double blind, randomised, placebo controlled adjunctive 
trial will investigate the benefits of 200 mg/day of minocycline treatment, in addition to any usual treatment, as an adjunctive 
treatment for moderate-severe major depressive disorder. Sixty adults are being randomised to 12 weeks of treatment (with 
a 4 week follow-up post-discontinuation). The primary outcome measure for the study is mean change on the Montgomery- 
Asberg Depression Rating Scale (MADRS), with secondary outcomes including the Social and Occupational Functioning 
Assessment Scale (SOFAS), Clinical Global Impressions (CGI), Hamilton Rating Scale for Anxiety (HAM-A), Patient Global 
Impression (PGI), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and Range of Impaired Functioning Tool 
(LIFE-RIFT). Biomarker analyses will also be conducted at baseline and week 12. The study has the potential to provide new 
treatment targets, both by showing efficacy with a new class of ‘antidepressant’ but also through the analysis of biomarkers 
that may further inform our understanding of the pathophysiology of unipolar depression.
KEY WORDS: Minocycline; Depression; Clinical research protocol; Inflammation; Oxidative stress.
INTRODUCTION
The World Health Organisation’s Global Burden of 
Disease report cited major depression as the fourth leading 
cause of disease burden, as measured by disability-ad-
justed life years, and the leading cause in terms of years 
lived with disability.1) This infers that major depression is 
possibly one of the most protracted and disabling illness, 
associated with great societal costs, of all modern medical 
conditions. A pertinent factor intertwined with such a crip-
pling course is the overall poor treatment outcome for ma-
jor depressive disorder (MDD). Despite having been tra-
ditionally viewed with a comparatively favourable prog-
nosis within psychiatric disorders, remission and func-
tional recovery are uncommon in practice.
One of the many factors underlying the poor treatment 
outcome of MDD is that, by and large, it is a syndrome of 
heterogeneous and imperfectly understood aetiology. 
Traditionally, MDD was believed to be caused by a dys-
function of neurotransmission, focused initially on the se-
rotonergic, and later the noradrenergic pathways however 
recently it has been postulated that while alterations in 
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neurotransmitter levels and function are present (includ-
ing glutamate and gamma-aminobutyric acid [GABA] in ad-
dition to serotonin and noradrenaline), these may not be 
the primary aetiological basis of the disorder. Indeed, this 
notion is supported by the lack of complete efficacy for up 
to 30% of people with MDD by treatment with serotonin 
and noradrenaline reuptake inhibitors, directly effecting 
neurotransmitter levels in the brain.2)
Activation of immune-inflammatory pathways includ-
ing changes in pro-inflammatory and cell-mediated im-
mune (CMI) cytokines have been documented ex-
tensively in MDD. Increased levels of pro-inflammatory 
and CMI cytokines including interleukin-1 (IL-1), IL-2, 
IL-6, IL-8, IL-12, interferon-γ (IFN-γ) and tumour ne-
crosis factor-α (TNF-α)2) are reported in MDD. 
Conversely, treatment with cytokines such as IFN-α have 
been related to decreased mood and increased depressive 
symptoms.3) Antidepressant treatments are believed to re-
duce the imbalanced cytokine levels in MDD. While there 
is, at present, a paucity of studies directly investigating 
changes pre- and post-antidepressant treatment, there is 
evidence to suggest that some antidepressants normalize 
cytokine levels and this may be an additional therapeutic 
target, secondary to their effects on neurotransmitters.4)
In depression, the role of nitro-oxidative stress has been 
explored in a small collection of studies. Peet et al.5) pre-
sented evidence of depleted levels of omega-3-fatty acids 
in MDD, while Maes et al.6,7) showed a significantly low-
ered oxidative potential index in fatty acids and lower con-
centrations of serum vitamin E, a fat-soluble antioxidant, 
in MDD compared with healthy volunteers. Bilici et al.8) 
showed decreased levels of the antioxidant enzyme, gluta-
thione peroxidase. Similarly, the lack of adequate anti-
oxidant defence in MDD is evidenced by increases in oxi-
dative stress markers. Lipid peroxidation products have 
been found to be significantly higher in MDD when com-
pared to controls.8,9) Furthermore, these alterations may 
return to normal after antidepressant treatment.8,10) Higher 
serum levels of 8-hydroxy-2’-deoxyguanosine (8-OhdG), 
a biomarker of DNA damage, were found in those with 
MDD than in controls.11) The levels of inducible nitric-ox-
ide (NO) synthase (iNOS) are higher in depression, while 
there is evidence of hyper-nitrosylation, the formation of 
NO-adducts.12,13) Individually, these studies are limited by 
their small sample sizes and restricted focus of attention, 
but they conglomerate to provide cogent support for the 
oxidative stress hypothesis for depression.
Finally, one of the other major targets emerging in dis-
covering the underlying aetiology of MDD are alterations 
generally known as neuroprogression; that is lowered 
neurogenesis and neuroplasticity, cell loss and activation 
of apoptotic.14) There are several identified neurotrophins 
in the brain that have been investigated in MDD. These in-
clude, brain-derived neurotrophic factor (BDNF), neuro-
trophin-3 (NT-3), and glial cell line-derived neurotrophic 
factor. In depression, these factors have been shown to be 
reduced and this may contribute the pathophysiology of 
the disorder.15,16) Furthermore, these neurotrophins are in-
fluenced by oxidative stress and inflammatory mediators, 
thereby creating an integrated system of pathophysiology 
that may underlie depression. Similar to inflammatory 
changes, alterations in neurotrophins have been found to 
be somewhat reversed following treatment and remission 
of symptoms.15,16) Together, these changes in oxidative in-
flammatory and neurotrophic factors are thought to play a 
pivotal role in the process of neuroprogression that is op-
erative in mood disorders.17)
Minocycline has been shown to have properties that 
may address these pathologies in depression. Minocycline 
has been shown to have antioxidant properties, making it 
appealing as a potential treatment for depression given the 
perturbations in antioxidant defences in MDD.18) In terms 
of reducing free radicals, minocycline has been shown to 
dose-dependently decrease nitrite levels and nitric oxide 
synthase expression following lipopolysaccaride (LPS) 
treatment.19) Rise in NO levels in response to 3-nitro-
propioic acid (3-NP; an inhibitor of the electron transport 
enzyme succinate dehydrogenase) was also attenuated us-
ing minocycline.20)
Similarly, minocycline was shown to attenuate in-
creases in malondialdehyde (a marker of lipid perox-
idation), following 3-NP treatment.20) Lipid peroxidation 
and free radical generation were also shown to be de-
creased in ischemic mouse forebrain following minocy-
cline treatment.21) Furthermore, minocycline has been 
shown to prevent increases in antioxidants in response to 
oxidative stress. In rat brain homogenates, minocycline 
was found to reduce increases in catalase and succinate 
dehydrogenase following 3-NP treatment.20) Conversely, 
minocycline treatment has not been shown to affect the re-
duced glutathione/oxidised glutathione (GSH/GSSG) ra-
tio following traumatic brain injury in adult mice.22)
Minocycline has also has reported anti-inflammatory 
effects that are not related to its microbial properties, but 
rather due to its purported inhibition of microglial 
activation. High dose minocycline is reported to reduce 
IL-1β levels following traumatic brain injury.22) This has 
also been replicated in MDMA-treated rats.23) Minocy-
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cline has also been found to reduce prostaglandin-E2 
(PGE2) and inhibit COX-2 expression in a dose-depend-
ent manner.19) Rises in TNF-α levels were also attenuated 
following minocycline treatment following administra-
tion of 3-NP. 20) These factors are especially relevant to 
MDD where increased levels of cytokines are reported.
In MDD there are reported decreases in neurotrophic 
factors such as BDNF and Bcl-2. Minocycline has been 
shown to significantly increase Bcl-2 RNA expression 
both alone, and in the presence of oxidative stress 
(hydrogen peroxide treatment).24) Similarly, minocycline 
has been shown to increase nerve growth factor-induced 
PC12 neuronal growth in a dose-dependent manner.25)
Minocycline has also been shown to be neuroprotective 
by preventing cell loss. In mouse models of traumatic 
brain injury, minocycline has been shown to reduce lesion 
volume.21,26) In one study modelling cerebral ischemia, 
minocycline was shown to reduce inflammation, but also 
decreased neurogenesis (shown by BrdU staining).27) 
However, this has been disputed in a similar study show-
ing minocycline increased BrdU expression and reduced 
microglia activation.28) Dosing and occlusion strategies 
may explain differences in results. Using hydrogen per-
oxide to attenuate insulin-like growth factor-1-promoted 
neuronal survival, minocycline was shown to prevent this 
loss of neuronal survival.29) Minocycline is also reported 
to prevent excitotoxic-induced cell death following 
NMDA treatment.30) The latter is especially relevant to the 
current study, as changes in glutamate pathways have 
been reported in MDD.
Following glutamate treatment, minocycline-treated 
rat cortical neurons were found to have increased cell via-
bility compared to controls, indicating decreased gluta-
mate-induced neurotoxicity.21,31) Studies have found re-
ductions in MK-801-induced disruptions in prepulse in-
hibition, and both N-methyl-D-aspartate (NMDA) antag-
onist- and methamphetamine-induced hyperlocomotion 
(two behavioural models associated with psychotic symp-
toms) in mice treated with minocycline.32,33)
There is preclinical data indicating benefits of minocy-
cline in models investigating depressive-like behaviour. 
In a study involving both independent and co-admin-
istration of minocycline in rats, minocycline was shown to 
be effective in the Porsolt swim test. Sub-threshold doses 
were of both current antidepressants and glutamate antag-
onists in combination with sub-threshold doses of mino-
cycline were also shown to have antidepressant effects.34) 
Conversely, in a study involving adult male Sprague- 
Dawley rats, the same dose of minocycline was shown to 
have no effect on swim times in the Porsolt swim test.35)
In a more recent study, learned helplessness was used as 
a model of depression and intracerebroventricular mino-
cycline treatment was explored. The study found that rats 
treated with minocycline had improved performance on 
the conditioned avoidance test (mild foot shock) and this 
did not correlate to changes in locomotor activity. This 
suggests the effects of minocycline are anti-depressant. 
The study found biological correlates with serotonin turn-
over in the orbitofrontal cortex; being increased in rats 
with learned helplessness and this was not altered by min-
ocycline treatment. However, there were no changes to se-
rotonin in other brain regions investigated. No changes to 
dopamine levels were reported although the data sug-
gested decreased dopamine levels in rats who acquired 
learned helplessness. Interestingly, although no deficit in 
dopamine was reported, minocycline caused an increase 
in dopamine levels in the amygdala. Finally, BDNF levels 
were reduced following the acquisition of learned help-
lessness and these remained unchanged following mino-
cycline treatment.36)
Taken together these data regarding the mechanisms of 
action of minocycline mirror many of the deficits seen in 
MDD. It is not surprising that minocycline has already 
been put forward as a potential antidepressant,37) but what 
is surprising is that to date, no clinical trials have been per-
formed, or are currently registered with the major clinical 
trials registry.
We have reviewed the literature regarding minocy-
cline’s use, to date, in psychiatry.18) Initial interest began 
with case reports in schizophrenia, reporting serendip-
itous reductions in psychotic symptoms following mino-
cycline treatment.38) Following on from these findings, the 
same research group conducted an open label study of 22 
people diagnosed with schizophrenia. These participants 
were given 300 mg/day of minocycline and were shown to 
have reduced symptoms after eight weeks of treatment. 
These participants had either been treatment resistant in 
the past or were currently not responding to treatment. No 
adverse events were reported following the eight-week 
treatment phase.39) The first double blind, placebo con-
trolled trial in schizophrenia investigated recently diag-
nosed (＜5 years) participants (minocycline: n=36, con-
trol: n=18) who were currently experiencing symptoms 
(Positive and Negative Syndrome Scale [PANSS] ＞60). 
Participants were assigned to either 200 mg/day of mino-
cycline or placebo in addition to an atypical antipsychotic 
medication for a total of 22 weeks. Results showed im-
provements in negative and cognitive symptoms, as well 
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as overall improvements in functioning.40)
Specific to depression, a case report regarding an in-
dividual with bipolar disorder who has predominantly de-
pressive episodes was reported by Levine et al.41) While 
admitted as an inpatient, the individual received 150 
mg/day of minocycline and within four days had reported 
an attenuation of depressive symptoms. These improve-
ments remained following withdrawal of minocycline 
treatment.41) To provide further clinical support for the 
proposed trial, an open-label study has been conducted in 
a cohort of participants diagnosed with psychotic depres-
sion (major depression with psychotic features). After 6 
weeks of treatment with minocycline (150 mg/day) im-
provements were not only seen in psychotic symptoms, 
but dramatic reductions in depression symptoms were al-
so reported. Based on both the biochemical indication and 
the clinical observations, minocycline may have anti-
depressant effects. The current study aims to explore the 
potential of minocycline as an adjunctive treatment for 
unipolar depression.
Aims
Using a randomised placebo controlled trial, we aim in 
this pilot study to test the efficacy of adjunctive minocy-
cline (100 mg twice daily) in the acute treatment of uni-
polar depression to determine if: 
1. Twelve weeks treatment of 200 mg/day minocycline 
treatment reduces severity of depression compared 
to individuals taking treatment as usual: Primary 
aim.
2. Twelve weeks with 200 mg/day minocycline treat-
ment will improve self-reported symptom burden, 
quality of life, overall functioning and clinical im-
pression and reduce symptoms of anxiety.
3. There are continued benefits following cessation of 
trial treatment assessed at 4 weeks following dis-
continuation.
4. Whether 12-weeks treatment with 200 mg/day min-
ocycline reduces serum markers of inflammation. 
5. Whether the change in immune-inflammatory and 
nitro-oxidative markers correlates with change in 
depressive symptomatology.
Primary Hypothesis
1. Twelve-weeks of adjunctive minocycline treatment 
will be superior to placebo for reducing symptoms 
of depression using the Montgomery-Asberg 
Depression Rating Scale (MADRS).
Secondary Objectives/Hypotheses
2. Twelve weeks of adjunctive minocycline treatment 
will be superior to placebo for reducing clinical 
global status, and improving quality of life and func-
tioning based on validated rating scales.
3. Those who were taking the minocycline treatment 
will have better outcomes 4 weeks post-treatment 
discontinuation, based on symptomology, quality of 
life and functioning than those taking the placebo.
4. Those taking minocycline treatment will have re-
duced levels of inflammatory and oxidative stress 
(lipid peroxidation) levels in peripheral (blood) 
samples.
5. Clinical change will correlate with discernible 
changes in inflammatory and oxidative stress levels 
in the peripheral sample.
METHODS
Study Design
This is a 12-week, parallel group, double-blind, rando-
mised-control trial in which 60 participants with moder-
ate-to-severe MDD will be allocated receive either 200 
mg/day minocycline or placebo, in addition to treatment 
as usual (medication, psychotherapy or any other treat-
ment). 
Assessments are completed at baseline and weeks 0, 2, 
4, 8 and 12. A follow-up (post-treatment discontinuation) 
assessment is completed at week 16. Randomisation is 
carried out according to the International Conference on 
Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use (ICH) guidelines 
by an independent researcher. Participants are allocated to 
treatment groups using randomly permuted blocks (4×2) 
to maintain approximately equal group sizes over time.
Identity of Investigational Product and Comparators
Minocycline: 200 mg/day of minocycline (given as 100 
mg twice daily) will be used in the study.
Placebo: Placebo tablets (starch) matched in appear-
ance and taste will be used.
Setting
The current study is being led by Dr. Olivia Dean from 
Deakin University, in collaboration with Professor (Prof.) 
Michael Berk from Deakin University/Barwon Health, 
Prof. Chee Ng from the Univesrity of Melbourne/The 
Melbourne Clinic and Profs. Michael Maes and Buranee 
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Kanchanatawan from Chulalongkorn University. The 
study will be conducted at three sites; Barwon Health and 
The Melbourne Clinic, both based in Victoria, Australia 
and Chulalongkorn University, Bangkok, Thailand.
PROCEDURE
Selection of Study Population
Potential participants are identified through referral by 
both the private and public treating sectors and by com-
munity advertisements. Participants expressing interest in 
the trial are contacted and invited to participate in a 
screening interview. Informed consent is obtained at the 
initial interview, prior to any study procedures commenc-
ing.
Inclusion criteria
For inclusion in the study, participants must fulfil all of 
the following criteria:
∙ Aged 18 years or over
∙ Capacity to consent to the study and to follow its in-
structions and procedures
∙ Fulfil the Diagnostic and Statistical Manual of 
Mental Disorders 4th edition, text revision (DSM- 
IV-TR) diagnostic criteria for MDD, single episode 
or recurrent scoring 25 or over on the MADRS, at the 
baseline visit 
∙ Participants on antidepressant therapy need to have 
been on the same treatment for at least two weeks pri-
or to randomisation
∙ Utilising effective contraception (other than the con-
traceptive pill due to drug interactions) if female of 
child-bearing age and sexually active
Exclusion criteria
Participants are ineligible to enter the trial under the fol-
lowing conditions:
∙ Concurrent diagnosis of bipolar disorder I, II or not 
otherwise specified
∙ Three or more failed adequate trials of antidepressant 
therapy for the current major depressive episode or 
electroconvulsive therapy for the current major de-
pressive episode
∙ Known or suspected clinically unstable systemic 
medical disorder (including a pre-existing infectious 
illness requiring tetracycline antibiotic treatment)
∙ Pregnancy or breastfeeding
∙ Contraindications to tetracyclines, including allergy 
or other intolerance; prior tetracycline use within 2 
months of baseline visit
∙ Current treatment with ＞5 mg beta caretone or 
＞300μg retinol equivalent
∙ Current treatment with isotretinoin or etretinate
∙ Current treatment with anticoagulants (excluding as-
pirin)
∙ Current treatment with methoxyflurane
∙ Current treatment with penicillin 
∙ Females of childbearing age currently relying solely 
on the contraceptive pill as contraception
∙ Current enrolment in another clinical trial
∙ Participants requiring treatment with antacids con-
taining aluminium, calcium or magnesium and prep-
arations containing iron must take these preparations 
at least 2 hours before or after minocycline admini-
stration. This should be clearly stated at each visit.
Withdrawal of patients from treatment or assessment
Participants will be withdrawn from the trial under the 
following conditions:
∙ Failure to take the trial medication for seven consec-
utive days
∙ Cessation of effective contraception or confirmed 
pregnancy
∙ Withdrawal of consent 
∙ Emergence of serious adverse events suspected to be 
associated with the trial medication
∙ Unavoidable commencement on anticoagulants (other 
than aspirin), ＞5 mg beta caretone or ＞300 μg ret-
inol equivalent, isotretinoin or etretinate, the contra-
ceptive pill, methoxyflurane or penicillin.
∙ Participants who require tetracycline antibiotic treat-
ment during the course of the study will be withd-
rawn.
Note: In cases of the emergence of adverse effects of 
minocycline treatment (such as vertigo), trial medication 
will be stopped for five days and then recommenced. 
Participants will be contacted two days following re-
commencement to determine if adverse effects have 
returned.
Randomisation - Method of Assigning Patients to 
Treatment Groups
After the baseline assessment has been completed, the 
participant will be randomised to one of the two treatment 
groups. Randomisation is enabled by a computer-based 
random number generator. Participating pharmacies have 
the randomisation code, to unblind participants if re-
quired. The randomisation will be double-blind and only 
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the pharmacist will know which group the participant has 
been allocated to. Blindness will be maintained by ensur-
ing that the packaging, appearance and colour of minocy-
cline and placebo capsules are identical. Additionally, a 
third blinding aspect has been included, whereby all data 
analysis conducted by the statistician is conducted blind to 
treatment arms.
Participants are randomised strictly sequentially, as 
they are eligible for randomisation. Randomisation 
schemes are organised and administered centrally by the 
Innovations in Mental and Physical Health Aand Clinical 
Treatments Strategic Research Centre (IMPACT SRC). 
Each participant will have a unique identification number 
(Participant ID#) for anonymous data analysis. 
Accountability
The study treatments will only be used as directed in the 
protocol. From visit 1, participants will be requested to re-
turn all unused investigational products and empty con-
tainers to the investigator or research assistants. Records 
of overall dispensing and returns will be calculated and 
documented by the pharmacist involved in the study. 
Adherence to medication will be assessed by self-report 
and a pill count. This data will be used to calculate com-
pliance with medication for analysis purposes.
VARIABLES AND INSTRUMENTS
Assessment of Inclusion and Exclusion Criteria
∙ Unipolar depression (and the absence of bipolar dis-
order) will be confirmed using the Mini International 
Neuropsychiatric Interview for DSM-IV (MINI- 
Plus) version 5. 
∙ Depressed severity will be established with the 
MADRS (moderate-to-severe depression defined as 
MADRS ≥25).
∙ Stability of current treatment and use of previous an-
tidepressants and contraindicated medications will 
be assessed at the screening visit by the researcher 
based on questions in the case report form.
∙ Urine pregnancy tests will be conducted on females 
of child-bearing age to exclude pregnancy.
Enrolment and Demographic Variable(s)
The following variables will be assessed for enrolment 
in the study and for demographic purposes:
∙ Medical history 
∙ Previous medication 
∙ Basic physical examination (pregnancy test for fe-
males, height and weight)
∙ Family history
∙ Demographics (age, gender, socioeconomic status, 
educational attainment)
Efficacy Measure(s)
A battery of validated outcome measures, focussing on 
both depressive symptomatology and global clinical and 
functional status, will be used at baseline and at weeks 2, 
4, 8 and 12 post-baseline intervals. Efficacy measures in-
clude:
∙ MADRS (primary outcome)
∙ Clinical Global Impression - Improvement (CGI-I) 
and – Severity (CGI-S) scales
∙ Patient Global Impression - Improvement (PGI-I) 
scale
∙ Hamilton Anxiety Rating Scale (HAMA)
Functioning and Quality of Life Measures
∙ Quality of life will be assessed using the Quality of 
life Enjoyment and Satisfaction Questionnaire - 
Short Form (Q-LES-Q-SF). We will look at change 
in score over time at 12 and 16 weeks.
∙ The Social and Occupational Functioning Scale 
(SOFAS) will be used to measure of psychosocial 
(social and occupational) functioning over time at 12 
and 16 weeks.
∙ The Range of Impaired Functioning Tool 
(LIFE-RIFT) will also be used to measure levels of 
functioning over time at 12 and 16 weeks.
Predictors and Moderators of Response
∙ The Standardised Assessment of Personality-Abbre-
viated Scale (SAPAS) will be used to identify those 
with suspected personality disorders and this will be 
used as a covariate in the analysis and also used as a 
variable of interest in examining treatment response.
∙ Analysis of biomarkers of oxidative and in-
flammatory markers will be used to determine how 
treatment response (if present) correlates to changes 
in biological markers.
∙ Changes in biomarkers will be used to explore the 
underlying pathophysiology of depression.
Assessment of Safety
Side-effects will be assessed with open questions and 
recorded using the standardised adverse events sheet in-
cluded in the CRF.
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Biomarkers
Participants will also be asked to provide two blood 
samples for research analysis. The provision of the blood 
samples is optional and does not affect participation in the 
clinical trial. These samples will be collected at baseline 
and the end of the treatment phase (week 12) and will in-
volve the collection of a 3 tubes of blood (approximately 
30 ml, 2 tablespoons) at each collection. This sample will 
be processed (centrifuged and aliquoted into 500 μl ali-
quots) and frozen at −80oC until the time of analysis.
The research sample will be collected to investigate in-
flammatory and oxidative stress markers to determine if 
and how these treatments are impacting at a biological lev-
el (in addition to the subjective perception of symptom 
change). These markers will include inflammatory cyto-
kines, c-reactive protein, oxidative stress markers such as 
malondialdehyde, oxidised low-density lipoprotein, mea-
sures of antioxidant levels, markers of DNA damage 
(8-hydroxy-2-deoxyguanosine), and growth factors in-
cluding insulin-like growth factor, epidermal growth fac-
tor and BDNF.
DATA MANAGEMENT
Description of Analysis Sample
The sample to be included in the analyses will be all the 
participants who give consent to participate in the study 
and who meet all inclusion criteria and no exclusion 
criteria. Participants must also complete at least one 
post-baseline visit for their data to be included in the 
analysis.
Method of Statistical Analysis
All analyses will be conducted in accordance with the 
ICH E9 statistical principles, and are based on all rando-
mised participants with at least one post-baseline ob-
servation (intention to treat population). Primary analyses 
will be undertaken on an intention-to-treat basis, includ-
ing all participants as randomised, regardless of treatment 
actually received. Mixed- model repeated measures 
(MMRM) analyses will be used to analyse change in 
MADRS score because it has been demonstrated to be su-
perior to the last observation carried forward method for 
handling missing data in longitudinal designs. The 
MMRM model includes the fixed, categorical effects of 
treatment, investigator, visit, and treatment-by-visit inter-
action, as well as the continuous, fixed covariates of base-
line score and baseline score-by-visit interaction. The 
MMRM includes all available data at each time point. 
Results from the analysis of dichotomous data will be pre-
sented as proportions, with 95% confidence interval, and 
Fisher’s exact p-value where appropriate. Non-parametric 
statistics will be used when assumptions for parametric 
methods are violated. Effect sizes will be calculated using 
Cohen’s guidelines. All tests of treatment effects will be 
conducted using a two-sided alpha level of 0.05 and 95% 
confidence intervals. Significance will be defined as p≤
0.05.
Sample Size and Power
A total of 60 participants meeting the DSM-IV-TR cri-
teria for MDD, and experiencing moderate to severe ill-
ness symptomatology, will be recruited. The primary out-
come measure will be change in MADRS score at week 
12. For a two tailed analysis42) with α=0.05, Zα = 1.96 
and with β=0.2, Zβ = 0.842, N=60 (n=30 in each arm), 
the study will be powered at 80% to detect a true differ-
ence in rating scale score between placebo and minocy-
cline treated groups if the difference of the means is not 
less than 0.724 times the standard deviation in the control 
group (effect size).
An effect size of 0.4 or greater for difference in MADRS 
scores in randomised controlled trials of antidepressants 
versus placebo has been suggested as necessary to suggest 
clinical utility for an antidepressant used as monotherapy. 
Effect sizes of 0.28 to 0.51 have been reported for differ-
ence in MADRS score in trials of citalopram and escitalo-
pram after 8 weeks of treatment.43) This suggests that at 
N=60 the proposed depression study may not be suffi-
ciently powered to detect small effect size differences be-
tween placebo and minocycline treated groups for 
changes in MADRS score if the efficacy of minocycline is 
not greater than conventional antidepressant monothe-
rapy. However, for a pilot study a sample size of 60 should 
be sufficient to demonstrate trends that would indicate a 
need for a larger trial.
RESULTS AND DISCUSSION
The study is currently being conducted at the two 
Victorian sites and has relevant approval from the Human 
Research and Ethics Committees. The study is planned to 
begin recruitment at the Thailand site in May 2014, with 
the relevant aprpovals in place.
The study has recruited 15 participants to date and is 
planning to complete the recruitment phase in 2014.
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CONCLUSIONS
Given the paucity of new therapies for unipolar depres-
sion and the burden the illness costs not only at a personal 
level, but for the wider community and the associated 
health-economics concerns, this trial is timely. The study 
may not only provide evidence of a novel therapy for uni-
polar depression, but may also assist in driving new targets 
of therapeutic pursuit through the exploration of bio-
markers. Overall, we are hopeful that this study may have 
significant benefit for those with unipolar depression.
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